Peginterferon alfa-2a

This article relies on references to primary sources or sources affiliated with the subject, rather than references from independent authors and third-party publications. Please add citations from reliable sources. (November 2008)

Peginterferon alfa-2a

Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a605029
Pregnancy cat.	?
Legal status	?
Routes	subcutaneous
Identifiers
CAS number	215647-85-1 N
ATC code	L03AB11 L03AB61 (in combinations)
DrugBank	DB00008
UNII	Q46947FE7K N
KEGG	D02748 Y
ChEMBL	CHEMBL1201560 N
Chemical data
Formula	C860H1353N227O255S9
Mol. mass	19241 g/mol (unpegylated) 40000 g/mol (pegylated)
N (what is this?)  (verify)

Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.

Uses

This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.

Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.^{[citation needed]}

Host genetic factors influencing treatment response

For genotype 1 hepatitis C treated with Pegylated interferon-alpha-2a or Pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature ^[1], showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Later report from Nature ^[2] demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.

See also

• Interferon
• PEGylation

References

External links

• Interferon and hepatitis c at pegasys.com
• PMPRB at pmprb-cepmb.gc.ca
• Chemical structure at hepalife.com
• MeSH Pegasys

This antiinfective drug article is a stub. You can help Wikipedia by expanding it. v t e

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. v t e